Want to see CHRS full AI Analyst Report?
CHRS Stock Chart & Stats
$1.98
-$0.05(-3.18%)
At close: 4:00 PM EST
$1.98
-$0.05(-3.18%)
Day’s Range― - ―
52-Week Range$0.71 - $2.62
Previous CloseN/A
Volume565.36K
Average Volume (3M)1.23M
Market Cap
$223.66M
Enterprise Value$109.28M
Total Cash (Recent Filing)$167.05M
Total Debt (Recent Filing)$54.37M
Price to Earnings (P/E)―
Beta1.31
Next Earnings
Jul 30, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.28
Shares Outstanding154,249,900
10 Day Avg. Volume792,979
30 Day Avg. Volume1,227,420
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)2.80
Price to Sales (P/S)4.05
P/FCF Ratio-1.23
Enterprise Value/Market Cap0.49
Enterprise Value/Revenue2.33
Enterprise Value/Gross Profit3.88
Enterprise Value/Ebitda-0.68
Forecast
1Y Price Target
$8.25Price Target Upside316.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.96
Revenue Forecast (FY)$61.63M
Bulls Say, Bears Say
Bulls Say
Commercial Traction For LOQTORZISustained commercial momentum (61% YoY sales growth, record patient starts and +21% account penetration) indicates durable adoption in oncology practice. Management's multi-year ramp targets imply predictable scaling potential, supporting durable revenue expansion if reimbursement and uptake continue.
Improved, Low-leverage Balance SheetMaterial balance-sheet improvement with minimal debt and positive equity reduces refinancing and solvency risk, giving management strategic flexibility. A conservative leverage profile supports funding commercialization and clinical milestones without immediate high-interest obligations, improving operational stability.
Strengthened Liquidity And Cost DisciplineA $54M capital raise plus $167M in liquidity and sustained expense cuts extend runway through key 2026–2027 readouts. Demonstrated spending discipline preserves cash for prioritized programs and commercialization, reducing near-term financing needs and enabling focused execution of clinical/commercial plans.
Bears Say
Deep, Persistent Cash BurnLarge negative operating and free cash flows indicate the company cannot self‑fund growth from operations and remains dependent on external financing. Persistent cash burn raises dilution and refinancing risk, constraining long‑term investment in commercialization and multiple clinical programs without successful readouts.
Sustained Operating And Net LossesExtremely negative operating and net margins versus modest revenue demonstrate an unsustainable cost-to-revenue structure. Even with revenue rebound, earnings volatility and large losses undermine the path to profitability absent meaningful revenue scale or structural cost reductions, limiting financial resilience.
Clinical And Regulatory Binary Risk For Tagmokitug (CCR8 Class)Mixed external CCR8 outcomes and immature internal data create a high binary risk for tagmokitug's clinical and regulatory trajectory. Key durability and survival endpoints need longer follow-up; unfavorable readouts or class skepticism could materially impair pipeline value and future oncology revenue prospects.
Coherus Biosciences News
CHRS FAQ
What was Coherus Biosciences’s price range in the past 12 months?
Coherus Biosciences lowest stock price was $0.71 and its highest was $2.62 in the past 12 months.
What is Coherus Biosciences’s market cap?
Coherus Biosciences’s market cap is $223.66M.
When is Coherus Biosciences’s upcoming earnings report date?
Coherus Biosciences’s upcoming earnings report date is Jul 30, 2026 which is in 24 days.
How were Coherus Biosciences’s earnings last quarter?
Coherus Biosciences released its earnings results on May 11, 2026. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of -$0.263 by -$0.007.
Is Coherus Biosciences overvalued?
According to Wall Street analysts Coherus Biosciences’s price is currently Undervalued.
Does Coherus Biosciences pay dividends?
Coherus Biosciences does not currently pay dividends.
What is Coherus Biosciences’s EPS estimate?
Coherus Biosciences’s EPS estimate is -0.25.
How many shares outstanding does Coherus Biosciences have?
Coherus Biosciences has 154,249,900 shares outstanding.
What happened to Coherus Biosciences’s price movement after its last earnings report?
Coherus Biosciences reported an EPS of -$0.27 in its last earnings report, missing expectations of -$0.263. Following the earnings report the stock price went down -12.308%.
Which hedge fund is a major shareholder of Coherus Biosciences?
Currently, no hedge funds are holding shares in CHRS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Coherus Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.25 (316.67% Upside)
$8.25 (316.67% Upside)
Blogger Sentiment
Bullish
CHRS Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 231.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
82.38%
12-Months-Change
Fundamentals
Return on Equity
-174.71%
Trailing 12-Months
Asset Growth
-28.31%
Trailing 12-Months
Company Description
Coherus Biosciences
Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the research, development, and commercialization of cancer immunotherapies across the United States. The company's commercialized products include several biosimilar therapies. These comprise UDENYCA, a long-acting granulocyte-colony stimulating factor biosimilar to Neulasta; YUSIMRY, an equivalent to Humira, prescribed for inflammatory conditions like rheumatoid arthritis, psoriasis, and Crohn's disease, which are characterized by heightened tumor necrosis factor (TNF) production; and CIMERLI, a Lucentis biosimilar aimed at treating specific ophthalmic disorders such as neovascular age-related macular degeneration, macular edema, and diabetic retinopathy. Beyond its commercial products, Coherus maintains a robust pipeline of investigational immunotherapies. This includes LOQTORZI, a novel, next-generation programmed death receptor-1 (PD-1) inhibitor; Casdozokitug, a recombinant human immunoglobulin G1 (IgG1) monoclonal antibody designed to target interleukin 27; CHS-114, a highly specific human afucosylated IgG1 monoclonal antibody targeting a chemokine receptor prevalent on Treg cells in the tumor microenvironment (TME); CHS-1000, an anti-ILT4 monoclonal antibody aimed at solid tumors; and GSK4381562, an antibody engineered to target CD112R on tumor cells. To support its endeavors, the company has forged several strategic alliances. These encompass a co-development and commercialization pact with Junshi Biosciences for toripalimab, as well as agreements with Surface and Adimab LLC. Its licensing portfolio includes arrangements with Bioeq AG, Genentech, Inc., Surface, and Vaccinex, Inc. Furthermore, Coherus has out-licensing agreements with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. Founded in 2010, the company currently operates as Coherus BioSciences, Inc., but is slated to officially rebrand as Coherus Oncology, Inc. in May 2025. Its headquarters are located in Redwood City, California.
CHRS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominantly positive operational and clinical picture: robust year-over-year LOQTORZI revenue growth (61% YoY), record new patient starts, fully enrolled randomized HCC study, multiple tagmokitug cohorts actively accruing, and a $54M capital raise that strengthens liquidity. These achievements are tempered by near-term seasonality and weather-related revenue disruption, mixed external CCR8-class data that increase binary risk for tagmokitug, and the need for longer follow-up to demonstrate durability and survival for regulatory endpoints. Cost control and expense reductions improve runway, but modest cash depletion and the potential for multiple concurrent development needs remain monitoring items. Overall, the highlights (strong sales growth, pipeline progress, funded trials) outweigh the lowlights (Q1 weather impact, CCR8-class uncertainty, and data maturity concerns).View all CHRS earnings summariesCHRS Stock 12 Month Forecast
Average Price Target
$8.25
▲(316.67% Upside)
Technical Analysis
Ownership Overview
1.24% Insiders
9.36% Mutual Funds
0.15% Other Institutional Investors
81.05% Public Companies and
Individual Investors